Cardiovascular Medication Use Before First Myocardial Infarction
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2012 by London School of Hygiene and Tropical Medicine.
Recruitment status was Active, not recruiting
University College, London
Information provided by (Responsible Party):
Emily Herrett, London School of Hygiene and Tropical Medicine
First received: September 21, 2012
Last updated: September 25, 2012
Last verified: September 2012
Large randomised trials have shown that cardiovascular medications prescribed to patients at high cardiovascular risk are effective in reducing the incidence of cardiovascular events. Their use is recommended in the United Kingdom and international guidelines (e.g. the National Institute of Clinical Excellence). However, these medications do not prevent cardiovascular events in all patients and there is now a body of research investigating the effects of cardiovascular medications on outcomes in myocardial infarction (MI), including clinical presentation, infarct size and post-MI mortality. However, the independent effects of cardiovascular drugs on post-MI all cause mortality are unclear, and there are limitations to many of the published studies in terms of their cardiovascular drug exposure data. This project utilizes prospectively collected data on cardiovascular drug use, and links to MI data from hospital and mortality records.
||Observational Model: Cohort
Time Perspective: Retrospective
||Cardiovascular Medication Prescriptions Before First Myocardial Infarction in Patients With and Without Previously Diagnosed Atherosclerotic Disease: an Analysis of Linked Prospectively Collected Electronic Healthcare Records
Primary Outcome Measures:
- All cause mortality [ Time Frame: Up to seven years ] [ Designated as safety issue: No ]
All cause mortality, using Office for National Statistics (ONS) mortality statistics
- Re-infarction [ Time Frame: One year after initial myocardial infarction ] [ Designated as safety issue: No ]
Reinfarction will be measured based on data from the General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Myocardial Ischaemia National Audit Project (MINAP) and Office for National Statistics (ONS) mortality data.
Secondary Outcome Measures:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||September 2013 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
The study population is comprised of patients with a first myocardial infarction who are registered at those General Practice Research Database (GPRD) practices that agreed to the linkage with the MINAP database, and whose practices are "up to standard" according to GPRD criteria. Practices taking part in the GPRD are chosen to be representative of all United Kingdom (UK) practices, and 98% of people in the UK are registered with a General Practitioner (GP). Therefore the GPRD should be a representative sample of the UK population.
Patients in GPRD practices which are deemed "up to standard" by GPRD criteria will be included if their practice agreed to be linked to the Myocardial Ischaemic National Audit Project (MINAP), Hospital Episode Statistics (HES) and Office for National Statistics (ONS) datasets.
Patients must have at least one year of GPRD "up to standard" registration before the date of first myocardial infarction.
Age over 18. First myocardial infarction occurring between 1st January 2003 and 31st December 2008, as recorded in the HES data or MINAP.
Patients will be excluded if they do not fulfil one of the inclusion criteria.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01692795
|London School of Hygiene and Tropical Medicine
|London, United Kingdom, WC1E 7HT |
London School of Hygiene and Tropical Medicine
University College, London
||Emily Herrett, MSc
||London School of Hygiene and Tropical Medicine
||Harry Hemingway, FRCP
||University College, London
No publications provided
||Emily Herrett, Principle Investigator, London School of Hygiene and Tropical Medicine
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 21, 2012
||September 25, 2012
||United Kingdom: Research Ethics Committee
Keywords provided by London School of Hygiene and Tropical Medicine:
Lipid lowering agents
Angiotensin Receptor Blockers
Blood pressure lowering drugs
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 01, 2015